Therapy News and Research

RSS

UAB receives grants to investigate novel approaches to treat Parkinson's disease

The Michael J. Fox Foundation (MJFF) has awarded two research grants to UAB (University of Alabama at Birmingham) researchers to investigate novel approaches to treat Parkinson's disease.

13 Jul 2007

Wilmot Cancer Center studies new chemo pill for lymphoma

Doctors at the University of Rochester's James P. Wilmot Cancer Center are first in the world to study a new, targeted agent that zeroes-in on B-cell lymphomas. The new twice-a-day pill offers patients with recurrent disease another choice as their options grow thin.

12 Jul 2007

St. Jude study holds promise for improving neuroblastoma treatment

A treatment for neuroblastoma that lands a one-two punch works best when the second punch is timed to take maximum advantage of the first one, according to results of studies at St. Jude Children's Research Hospital.

12 Jul 2007

Startling discovery on the development of human embryonic stem cells

In this week's Nature, researchers of the McMaster Cancer and Stem Cell Research Institute show that human embryonic stem (ES) cells can actually produce distinctive niche cells, which then release stem-cell nourishing proteins to help keep their parents ticking over.

12 Jul 2007

Chemically-modified mitochondrial toxin could lead to a new molecularly-targeted chemo drug

A chemically-modified version of a mitochondrial toxin long used to control species of invasive fish in lakes has been found to selectively inhibit two "survival proteins" in cancer cells.

12 Jul 2007

Dietary glycemic index linked to risk of vision loss

Age-related macular degeneration (AMD) and its associated vision loss may be connected to the quality of carbohydrates an individual consumes.

12 Jul 2007

Next generation painkillers

Scientists studying one of nature's simplest organisms have helped to unravel the structure of a key molecule that controls pain in humans.

From The University of Manchester 12 Jul 2007

Baxter receives FDA approval for new dosage of Advate for hemophilia A

Baxter Healthcare Corporation announced that the U.S. Food and Drug Administration (FDA) has approved a new 3000 IU (5mL) dosage strength of ADVATE [Antihemophilic Factor (Recombinant), Plasma/Albumin-Free Method].

12 Jul 2007

New advance in search for effective treatment for human liver cancer

Researchers from the University of Pittsburgh School of Medicine report a significant new advance in the search for an effective treatment for human liver cancer in the July issue of Molecular Cancer Therapeutics.

12 Jul 2007

For older women HRT a risky option

According to an international study older women should not take Hormone Replacement Therapy (HRT).

12 Jul 2007

New use for a cell toxin found to inhibit survival proteins in cancer cells

A chemically-modified version of a mitochondrial toxin long used to control species of invasive fish in lakes has been found to selectively inhibit two "survival proteins" in cancer cells.

11 Jul 2007

No benefit from HRT for older women

New evidence confirms that hormone replacement therapy (HRT) should not be prescribed to older women who are many years past the menopause. The treatment will not help prevent chronic conditions such as heart disease in these women.

11 Jul 2007

Baxter presents findings from the ADAPT study

Baxter Healthcare Corporation has announced the presentation of findings from the ADAPT (Analysis of Data from ADVATE Prospective Trials) study program database showing a statistically significant relationship between the duration of time spent with factor VIII blood levels below one international unit per deciliter (1 IU/dL, one percent of normal factor VIII level) and an increase in the annual bleed rate in people with hemophilia A.

11 Jul 2007

Genetically engineered herpes simplex virus keeps arteries free-flowing

A genetically engineered herpes simplex virus, primarily known for causing cold sores, may help keep arteries "free-flowing" in the weeks following angioplasty or stent placement for patients, according to research published early in the online edition of PNAS (Proceedings of the National Academy of Sciences of the United States of America).

11 Jul 2007

Kaposi sarcoma tumors arise independently from multiple cells

Kaposi sarcoma is unique among cancers because most tumors grow from a small number of different cells, whereas nearly all other cancers arise from a single cell, according to a study published online July 10 in the Journal of the National Cancer Institute.

11 Jul 2007

Myomo receives FDA approval to market e100 NeuroRobotic System

Myomo, Inc. has announced that the company received U.S. Food and Drug Administration (FDA) 510(k) clearance to market the Myomo e100 NeuroRobotic System. Myomo's first product is a wearable, portable therapeutic modality designed to allow patients to self initiate and control movement of partially paralyzed limbs using their own biological signals.

11 Jul 2007

Court rules in favor of Massachusetts Eye and Ear Infirmary

The Massachusetts Eye and Ear Infirmary (MEEI) has announced that the United States District Court for the District of Massachusetts, Judge William G. Young, following a Nov. 6, 2006 jury decision, ruled in favor of MEEI on claims of unjust enrichment and unfair trade practices against QLT Inc.

11 Jul 2007

Incretin-based therapy offers alternative option for treating type 2 diabetes

A review of previous studies indicates that use of a class of medications known as “incretin-based therapy”, which act via certain pathways that affect glucose metabolism may provide modest effectiveness and favorable weight change outcomes for the treatment of type 2 diabetes and may represent an alternative to other hypoglycemic therapies.

11 Jul 2007

Catalyst Pharmaceutical Partners starts U.S. phase II trial of CPP-109 in patients with cocaine dependence

Catalyst Pharmaceutical Partners, Inc. a specialty pharmaceutical company that acquires or in-licenses, develops and commercializes prescription drugs for the treatment of drug addiction, today announced that it has initiated its randomized, double-blind, placebo-controlled U.S. Phase II clinical trial of CPP-109 in patients with cocaine dependence.

11 Jul 2007

Hydroxychloroquine may reduce risk of diabetes in patients with rheumatoid arthritis

Preliminary research suggests that use of the anti-malarial drug hydroxychloroquine may help reduce the risk of the development of diabetes in patients with rheumatoid arthritis, according to a study in the July 11 issue of JAMA .

11 Jul 2007